The concept that PR activation in the context of oestrogen-driven, ER+ breast cancer, can have an anti-proliferative effect has been postulated by others26,27 and it seems that the oestrogenic status can directly affect whether progestogens are pro-proliferative or antiproliferative. The gene discussed is ESR1; the disease is breast carcinoma.